โ€œASK THE DOCTORโ€ WITH DR. REBECCA GILBERT

Posted on by Phil Franchina

Q: I was recently told that carbidopa/ levodopa doesnโ€™t help tremor. Is...see more that true? A: No. Carbidopa/levodopa often helps tremor. However, in a certain percentage of people, tremors donโ€™t respond well as other symptoms of PD such as slowness and stiffness. Movement disorder physicians measure whether medication doses […]

Read More

CHAMPIONING HEALTH EQUITY: RESEARCHERโ€™S QUEST TO EXPAND ADVANCE CARE PLANNING IN HISPANIC PD COMMUNITIES

Posted on by Phil Franchina

As part of our 2024-2025...see more research funding, the American Parkinson Disease Association (APDA) was proud to award Danielle Shpiner, MD, an APDA Diversity in Parkinsonโ€™s Disease Research Grant, which is given to investigators exploring health inequities and/or differences among under-studied Parkinsonโ€™s […]

Read More

AMERICAN PARKINSON DISEASE ASSOCIATION FREE TWO-DAY VIRTUAL CONFERENCE RETURNS TO EDUCATE, EMPOWER, AND ENGAGE THE PD COMMUNITY

Posted on by Phil Franchina

Two days of learning, activities, and inspiration featuring top expertsFebruary 19 & 20, 2025 NEW YORK, NY, JANUARY 6,...see more 2025 โ€“ The American Parkinson Disease Association (APDA) is pleased to announce that registration is open for its third annual APDA Virtual Parkinsonโ€™s Conference. Following the overwhelming success of its first two years โ€“ which combined […]

Read More

EPA Bans TCE, a Solvent Linked to PD

Posted on by Phil Franchina

In an exciting development for the Parkinsonโ€™s disease (PD) community, the Environmental Protection Agency (EPA) banned two solvents, trichloroethylene...see more (TCE) and perchloroethylene, that are found in many common industry and household products such as cleaners, lubricants, and glue. Both have been found to contribute to the increased risk of various cancers and other health conditions. […]

Read More

Vyalev: A Newly-Approved Medication for Parkinsonโ€™s Disease Motor Fluctuations

Posted on by Phil Franchina

Breaking news! The first subcutaneous (under the skin) 24-hour infusion...see more of foslevodopa/foscarbidopa under the brand name Vyalev, was approved by the Food and Drug Administration on Oct 17, 2024. Produced by AbbVie, this medication for the treatment of motor fluctuations in Parkinsonโ€™s disease (PD) has already […]

Read More

MAKING HOPE POSSIBLE: APDA FUNDS INNOVATIVE RESEARCH

Posted on by Phil Franchina

From genetic causes of PD to the neurobiology of cognitive dysfunction, APDA-funded...see more researchers begin new work. The American Parkinson Disease Association (APDA) recently awarded $2.6 million to support innovative Parkinsonโ€™s disease (PD) research for the 2024-2025 funding year. Exciting projects will tackle a wide range of key areas […]

Read More

FROM STIGMA TO SUPPORT: RETHINKING MENTAL HEALTH IN THE PD COMMUNITY

Posted on by Phil Franchina

Tremors, rigidity, and mobility issues are commonly associated...see more with Parkinsonโ€™s disease (PD). However, beneath the visible symptoms are many non-motor symptoms that are not always outwardly noticeable. One of these quieter yet equally important aspects of this disease are the mental health challenges that […]

Read More

WHATโ€™S HAPPENING AT APDA

Posted on by Phil Franchina

Falls Prevention Did you know that September was Falls Prevention Awareness Month? Throughout the month,...see more we raised awareness through social media, emails, and conversations with the PD community. Some common causes of falls in PD are postural instability, freezing of gait, festinating gait, orthostatic hypotension, and more. Physical therapy and medication […]

Read More